Key result
The concomitant use of multiple QTc-prolonging drugs exponentially increases the risk of QTc interval prolongation and torsades de pointes tachycardia.
Why the study?
The prevalence of prolonged QTc interval and the risk of TdP tachycardia escalate exponentially with polypharmacy and concomitant QTc-prolonging drugs.
Concomitant use of multiple QTc-prolonging drugs exponentially increases the risk of fatal arrhythmias, highlighting the need for careful medication management.
Alerts clinicians to arrhythmia risk with multiple QTc-prolonging drugs; leaves open precise quantification pending higher-level evidence.
Highlights Acquired long QT syndrome is a rare disease, but the frequency of QTc prolongation increases with polypragmasia. Abstract Acquired long QT syndrome is a rare condition. However, the prevalence of prolonged QTc interval increases among patients with polypharmacy. The risk of both QTc interval prolongation and torsades de pointes (TdP) tachycardia escalates exponentially with the concomitant use of multiple QTc-prolonging drugs. This article explores the underlying mechanisms of the condition and methods to mitigate the risk of potentially fatal arrhythmias.
No takes yet. Share an insight, caveat, or question.
Kuzmin et al. (2025) conducted a review in Acquired long QT syndrome and QTc interval prolongation. Polypharmacy with multiple QTc-prolonging drugs was evaluated. The concomitant use of multiple QTc-prolonging drugs exponentially increases the risk of QTc interval prolongation and torsades de pointes tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: